Recent Quarter Total Invested
$7.34 B
Recent Quarter Institutional Ownership Percentage
90%
Total Invested of Last Quarter
$3.62 B
Ownership Percentage of Last Quarter
104.61%
Ultragenyx Pharmaceutical Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| BLACKROCK FUNDING, INC. /DE | 11/13/2024 | 5.83 M | $323.79 M | 100.00% | 6.10% |
| SANDS CAPITAL MANAGEMENT, LLC | 11/13/2024 | 5.12 M | $284.32 M | -4.42% | 5.36% |
| WELLINGTON MANAGEMENT GROUP LLP | 11/14/2024 | 4.17 M | $231.39 M | -8.58% | 4.36% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 11/14/2024 | 3.07 M | $170.47 M | 2.56% | 3.21% |
| ALKEON CAPITAL MANAGEMENT LLC | 11/14/2024 | 3.01 M | $167.30 M | 34.34% | 3.15% |
| STATE STREET CORP | 11/14/2024 | 2.66 M | $147.99 M | -1.22% | 2.79% |
| CLEARBRIDGE INVESTMENTS, LLC | 11/12/2024 | 2.43 M | $134.82 M | 3.11% | 2.54% |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 11/14/2024 | 1.98 M | $109.89 M | 2.82% | 2.07% |
| RTW INVESTMENTS, LP | 11/14/2024 | 1.97 M | $109.32 M | -39.63% | 2.06% |
| INVESCO LTD. | 11/12/2024 | 1.67 M | $93.01 M | 32.01% | 1.75% |
| BAKER BROS. ADVISORS LP | 11/14/2024 | 1.58 M | $87.55 M | 7.47% | 1.65% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 1.57 M | $87.30 M | 4.36% | 1.65% |
| ALLIANCEBERNSTEIN L.P. | 11/14/2024 | 1.55 M | $85.90 M | 1.20% | 1.62% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 11/14/2024 | 1.53 M | $84.75 M | 35.62% | 1.60% |
| ALYESKA INVESTMENT GROUP, L.P. | 11/14/2024 | 1.17 M | $64.99 M | 1,571.44% | 1.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 11/14/2024 | 1.15 M | $63.96 M | -44.15% | 1.21% |
| AQR CAPITAL MANAGEMENT LLC | 11/14/2024 | 1.04 M | $57.81 M | 975.56% | 1.09% |
| TWO SIGMA ADVISERS, LP | 11/14/2024 | 987,800 | $54.87 M | 123.38% | 1.03% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 925,910 | $51.43 M | 69.02% | 0.97% |
| AVORO CAPITAL ADVISORS LLC | 11/14/2024 | 830,000 | $46.11 M | 0.00% | 0.87% |
| MARSHALL WACE, LLP | 11/14/2024 | 822,012 | $45.66 M | -27.45% | 0.86% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 11/14/2024 | 783,944 | $43.55 M | 48.42% | 0.82% |
| BANK OF NEW YORK MELLON CORP | 11/12/2024 | 772,085 | $42.89 M | -1.26% | 0.81% |
| TWO SIGMA INVESTMENTS, LP | 11/14/2024 | 755,683 | $41.98 M | 32.97% | 0.79% |
| FIRST LIGHT ASSET MANAGEMENT, LLC | 11/14/2024 | 755,102 | $41.95 M | -21.60% | 0.79% |
| AVIDITY PARTNERS MANAGEMENT LP | 11/14/2024 | 752,000 | $41.77 M | -21.67% | 0.79% |
| VESTAL POINT CAPITAL, LP | 11/14/2024 | 750,000 | $41.66 M | -58.33% | 0.79% |
| BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 11/08/2024 | 724,182 | $40.23 M | -12.79% | 0.76% |
| CANDRIAM S.C.A. | 11/13/2024 | 713,092 | $39.61 M | 3.51% | 0.75% |
| MILLENNIUM MANAGEMENT LLC | 11/14/2024 | 710,689 | $39.48 M | -61.60% | 0.74% |
| POINT72 ASSET MANAGEMENT, L.P. | 11/14/2024 | 653,660 | $36.31 M | 21.10% | 0.68% |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 11/15/2024 | 633,715 | $35.20 M | 49.11% | 0.66% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11/12/2024 | 594,521 | $33.03 M | 10.58% | 0.62% |
| EMERALD ADVISERS, LLC | 10/29/2024 | 569,798 | $31.65 M | 17.08% | 0.60% |
| EAGLE HEALTH INVESTMENTS LP | 11/12/2024 | 561,700 | $31.20 M | 7.09% | 0.59% |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 11/12/2024 | 542,373 | $30.13 M | 46.49% | 0.57% |
| FRED ALGER MANAGEMENT, LLC | 11/14/2024 | 536,298 | $29.79 M | -2.30% | 0.56% |
| PICTET ASSET MANAGEMENT HOLDING SA | 11/12/2024 | 520,550 | $28.34 M | -6.51% | 0.55% |
| GOLDMAN SACHS GROUP INC | 11/14/2024 | 506,510 | $28.14 M | -19.54% | 0.53% |
| MORGAN STANLEY | 11/14/2024 | 467,836 | $25.99 M | -6.05% | 0.49% |
| GW&K INVESTMENT MANAGEMENT, LLC | 11/07/2024 | 466,569 | $25.92 M | 14.77% | 0.49% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 10/29/2024 | 429,302 | $23.85 M | 9.93% | 0.45% |
| AXA S.A. | 11/14/2024 | 425,390 | $23.63 M | 0.01% | 0.45% |
| SCHONFELD STRATEGIC ADVISORS LLC | 11/14/2024 | 400,833 | $22.27 M | -44.09% | 0.42% |
| NUVEEN ASSET MANAGEMENT, LLC | 11/14/2024 | 392,760 | $21.82 M | 92.32% | 0.41% |
| BIOIMPACT CAPITAL LLC | 11/13/2024 | 329,733 | $18.32 M | -13.35% | 0.35% |
| MAN GROUP PLC | 11/14/2024 | 327,203 | $18.18 M | -47.96% | 0.34% |
| DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 11/14/2024 | 294,723 | $16.37 M | 0.00% | 0.31% |
| CUTTER CAPITAL MANAGEMENT, LP | 11/14/2024 | 286,803 | $15.93 M | -21.42% | 0.30% |
| MACQUARIE GROUP LTD | 11/14/2024 | 275,927 | $15.33 M | 20.24% | 0.29% |
Ultragenyx Pharmaceutical Inc.institutional Ownership - Frequently Asked Questions
-
Who are the largest shareholders of RARE shares?
During the previous two years, 372 institutional investors and hedge funds held shares of Ultragenyx Pharmaceutical Inc.. The most heavily invested institutionals were:
BlackRock Funding, Inc. /DE: 5.83 M
SANDS CAPITAL MANAGEMENT, LLC: 5.12 M
WELLINGTON MANAGEMENT GROUP LLP: 4.17 M
PRICE T ROWE ASSOCIATES INC /MD/: 3.07 M
ALKEON CAPITAL MANAGEMENT LLC: 3.01 M
STATE STREET CORP: 2.66 M
-
What percentage of Ultragenyx Pharmaceutical Inc. stock is owned by institutional investors?
90.00% of Ultragenyx Pharmaceutical Inc. stock is owned by institutional investors.
-
How much institutional buying is happening at RARE ?
Institutional investors have bought a total of 82.73 M shares in the last 24 months. This purchase volume represents approximately $3.80 B in transactions.